Phosphodiesterase type-5 inhibitor use in type 2 diabetes is associated with a reduction in all-cause mortality

Simon G Anderson; David C Hutchings; Mark Woodward; Kazem Rahimi; Martin K Rutter; Mike Kirby; Geoff Hackett; Andrew W Trafford; Adrian H Heald

doi:10.1136/heartjnl-2015-309223

Article info

PDF

Cardiac risk factors and prevention

Original article

Phosphodiesterase type-5 inhibitor use in type 2 diabetes is associated with a reduction in all-cause mortality

Authors

Simon G Anderson Institute of Cardiovascular Sciences, University of Manchester, Manchester, UK The George Institute for Global Health, Oxford Martin School, University of Oxford, Oxford, UK PubMed articles Google scholar articles
David C Hutchings Institute of Cardiovascular Sciences, University of Manchester, Manchester, UK PubMed articles Google scholar articles
Mark Woodward The George Institute for Global Health, Oxford Martin School, University of Oxford, Oxford, UK The George Institute for Global Health, University of Sydney, Australia PubMed articles Google scholar articles
Kazem Rahimi The George Institute for Global Health, Oxford Martin School, University of Oxford, Oxford, UK PubMed articles Google scholar articles
Martin K Rutter Manchester Diabetes Centre, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK Centre for Endocrinology and Diabetes, Institute of Human Development, University of Manchester, Manchester, UK PubMed articles Google scholar articles
Mike Kirby The Centre for Research in Primary & Community Care, University of Hertfordshire, Hatfield, UK PubMed articles Google scholar articles
Geoff Hackett Department of Urology, Good Hope Hospital, Sutton Coldfield, UK PubMed articles Google scholar articles
Andrew W Trafford Institute of Cardiovascular Sciences, University of Manchester, Manchester, UK PubMed articles Google scholar articles
Adrian H Heald School of Medicine, and Manchester Academic Health Sciences Centre, University of Manchester, Manchester, UK Leighton Hospital, Crewe, UK PubMed articles Google scholar articles

Correspondence to Dr Simon G Anderson, Institute of Cardiovascular Sciences, University of Manchester, 3.24 Core Technology Facility, 46 Grafton Street, Manchester M13 9NT, UK; simon.anderson{at}manchester.ac.uk

View Full Text

Citation

Anderson SG, Hutchings DC, Woodward M, et al

Phosphodiesterase type-5 inhibitor use in type 2 diabetes is associated with a reduction in all-cause mortality

Heart 2016;102:1750-1756.

Publication history

Received December 22, 2015
Revised April 20, 2016
Accepted May 23, 2016
First published July 26, 2016.

Online issue publication

October 12, 2016

Article Versions

Previous version (26 July 2016).
Previous version (1 August 2016).
Previous version (24 August 2016).
You are viewing the most recent version of this article.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/

Log in using your username and password

Main menu

Log in using your username and password

You are here

Authors

Citation

Publication history

Article Versions

Request permissions

Copyright information

Read the full text or download the PDF:

Log in using your username and password